Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Molecular Effects of Doxorubicin on Choline Metabolism in Breast Cancer.

Cheng M, Rizwan A, Jiang L, Bhujwalla ZM, Glunde K.

Neoplasia. 2017 Aug;19(8):617-627. doi: 10.1016/j.neo.2017.05.004. Epub 2017 Jun 24.

2.

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.

Delgado-Goni T, Miniotis MF, Wantuch S, Parkes HG, Marais R, Workman P, Leach MO, Beloueche-Babari M.

Mol Cancer Ther. 2016 Dec;15(12):2987-2999. Epub 2016 Oct 7.

3.

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.

Serkova NJ, Eckhardt SG.

Front Oncol. 2016 Jul 15;6:152. doi: 10.3389/fonc.2016.00152. eCollection 2016. Review.

4.

Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.

Wijnen JP, Jiang L, Greenwood TR, Cheng M, Döpkens M, Cao MD, Bhujwalla ZM, Krishnamachary B, Klomp DW, Glunde K.

NMR Biomed. 2014 Jun;27(6):692-9. doi: 10.1002/nbm.3106. Epub 2014 Apr 24.

5.
6.

MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.

Lodi A, Woods SM, Ronen SM.

NMR Biomed. 2014 Jun;27(6):700-8. doi: 10.1002/nbm.3109. Epub 2014 Apr 2.

7.

New strategy for monitoring targeted therapy: molecular imaging.

Teng FF, Meng X, Sun XD, Yu JM.

Int J Nanomedicine. 2013;8:3703-13. doi: 10.2147/IJN.S51264. Epub 2013 Sep 30. Review.

8.

Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.

Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X.

PLoS One. 2013 Sep 27;8(9):e75864. doi: 10.1371/journal.pone.0075864. eCollection 2013.

9.

HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.

Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM.

PLoS One. 2013 Apr 23;8(4):e62610. doi: 10.1371/journal.pone.0062610. Print 2013.

10.

Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation.

Ripple MO, Kim N, Springett R.

J Biol Chem. 2013 Feb 1;288(5):2933-40. doi: 10.1074/jbc.M112.430082. Epub 2012 Dec 12.

11.

Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.

Lodi A, Woods SM, Ronen SM.

NMR Biomed. 2013 Mar;26(3):299-306. doi: 10.1002/nbm.2848. Epub 2012 Sep 3.

12.

Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Waerzeggers Y, Ullrich RT, Monfared P, Viel T, Weckesser M, Stummer W, Schober O, Winkeler A, Jacobs AH.

Br J Radiol. 2011 Dec;84 Spec No 2:S179-95. doi: 10.1259/bjr/76389842. Review.

13.

Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.

Beloueche-Babari M, Arunan V, Troy H, te Poele RH, te Fong AC, Jackson LE, Payne GS, Griffiths JR, Judson IR, Workman P, Leach MO, Chung YL.

Cancer Res. 2012 Feb 15;72(4):990-1000. doi: 10.1158/0008-5472.CAN-11-2688. Epub 2011 Dec 22.

14.

Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library.

Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G.

Nat Commun. 2011 Nov 22;2:545. doi: 10.1038/ncomms1562.

15.

Choline metabolism in malignant transformation.

Glunde K, Bhujwalla ZM, Ronen SM.

Nat Rev Cancer. 2011 Nov 17;11(12):835-48. doi: 10.1038/nrc3162. Review.

16.

MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer.

Glunde K, Jiang L, Moestue SA, Gribbestad IS.

NMR Biomed. 2011 Jul;24(6):673-90. doi: 10.1002/nbm.1751. Review.

17.

Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Moestue SA, Engebraaten O, Gribbestad IS.

Mol Oncol. 2011 Jun;5(3):224-41. doi: 10.1016/j.molonc.2011.04.001. Epub 2011 Apr 23. Review.

18.

Metabolic tumor imaging using magnetic resonance spectroscopy.

Glunde K, Bhujwalla ZM.

Semin Oncol. 2011 Feb;38(1):26-41. doi: 10.1053/j.seminoncol.2010.11.001. Review.

20.

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, Workman P, Leach MO.

Cancer Res. 2010 Jul 1;70(13):5507-17. doi: 10.1158/0008-5472.CAN-09-4476. Epub 2010 Jun 15.

Supplemental Content

Support Center